Gain access to the Pin-point™ base editing platform
Would you like the opportunity to license a novel pathway in the development of cell and gene therapeutic programs? The Pin-point base editing system offers the specificity of base editing combined with the potential for multiplex gene editing capabilities, making it an attractive technology for both cell and gene therapies.
Compared to traditional CRISPR technologies, which create double-stranded breaks in the DNA, this novel editing system uses a modified Cas enzyme that only nicks one strand of the DNA. This allows for a more controlled approach to gene disruption and base correction.
Please contact us if you are interested in integrating base editing into your therapeutic pipeline for cell or gene therapy programs and one of our dedicated corporate development partners will be in touch.
The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
Questions?
We’re here to help.
Contact us Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.